Search Results - "Davies, Rupert H."

Population pharmacokinetics of zanidatamab, an anti-HER2 biparatopic antibody, in patients with advanced or metastatic cancer by Proctor, Jeffrey R., Gartner, Elaina M., Gray, Todd E., Davies, Rupert H.

“…Purpose To characterize the pharmacokinetics (PK) of zanidatamab including evaluation of the impact of intrinsic and extrinsic patient factors. To investigate…”
Get full text

42273 Phase 1 Study in Healthy Adults of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALPN-303, a Dual BAFF/APRIL Antagonist for the Treatment of Autoimmune Blistering Diseases by Dillon, Stacey R., Davies, Rupert H., Lickliter, Jason D., Smith, Alina, Lessig, Mary C., Blanchfield, Lori, Sanderson, Russell J., Chunyk, Allison, Enstrom, Amanda, Zayed, Hany, Peng, Stanford L.

Get full text

Phase 1 Study in Healthy Adults of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALPN-303, a Dual BAFF/APRIL Antagonist for the Treatment of Autoimmune Glomerulonephritides (GN): TH-PO499 by Dillon, Stacey R., Harrison, Pille, Lickliter, Jason, Manjarrez, Kristi L., Smith, Alina, Lessig, Mary C., Sanderson, Russell J., Chunyk, Allison G., Lewis, Katherine, Zayed, Hany, Davies, Rupert H., Peng, Stanford

Get full text

Abstract 3914: ZW49, a HER2-targeted biparatopic antibody-drug conjugate for the treatment of HER2-expressing cancers by Hamblett, Kevin J., Hammond, Phil W., Barnscher, Stuart D., Fung, Vincent K., Davies, Rupert H., Wickman, Grant R., Hernandez, Andrea, Ding, Tong, Galey, Adam S., Winters, Geoffrey C., Rich, Jamie R., Babcook, John S.

“…Therapies targeting HER2 have transformed the treatment of patients with HER2-expressing breast and gastric cancers. Unfortunately, many patients recur…”
Get full text

Abstract 3912: Towards development of next-generation biparatopic ADCs using a novel linker-toxin with expanded therapeutic window by Davies, Rupert H., Barnscher, Stuart D., Chan, Peter W., Madera, Laurence, Rich, Jamie R., Vallejo, Marylou, Wickman, Grant R., Yin, Kevin, Fung, Vincent, Hamblett, Kevin J., Kaminker, Patrick G., Babcook, John S.

“…Antibody drug conjugate (ADC) therapies such as Kadcyla® and Adcetris® have significantly improved outcomes for patients. Despite these early advances, many…”
Get full text

Abstract 2935: ZW270, a conditionally masked IL-12 cytokine fusion protein displaying potent anti-tumor activity absent systemic toxicity by Poffenberger, Maya C., Bishop, Jennifer L., Blackler, Ryan J., Haworth, Kevin G., Booth, Steven, Hanson, Shalla, Proctor, Jeff R., Shao, I-Ting, Escalante, Nichole K., Siddappa, Dayananda, Smith, Joel, Anmole, Gursev, Konomura, Saki, Dawson, Nicholas A., Arrafi, Sifa, Lau, Desmond, Rowse, Gerry, Davies, Rupert H., von Kreudenstein, Thomas Spreter

“…IL-12 is a pleiotropic cytokine that potently stimulates anti-tumor cytotoxic T and NK cell mediated immunity. Recombinant IL-12 reduces tumor growth in…”
Get full text